APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancer

Acquired drug resistance to even the most effective anti-cancer targeted therapies remains an unsolved clinical problem. Although many drivers of acquired drug resistance have been identified1‒6, the underlying molecular mechanisms shaping tumor evolution during treatment are incompletely understood. The extent to which therapy actively drives tumor evolution by promoting mutagenic processes7 or simply provides the selective pressure necessary for the outgrowth of drug-resistant clones8 remains an open question. Here, we report that lung cancer targeted therapies commonly used in the clinic induce the expression of cytidine deaminase APOBEC3A (A3A), leading to sustained mutagenesis in drug-tolerant cancer cells persisting during therapy. Induction of A3A facilitated the formation of double-strand DNA breaks (DSBs) in cycling drug-treated cells, and fully resistant clones that evolved from drug-tolerant intermediates exhibited an elevated burden of chromosomal aberrations such as copy number alterations and structural variations. Preventing therapy-induced A3A mutagenesis either by gene deletion or RNAi-mediated suppression delayed the emergence of drug resistance. Finally, we observed accumulation of A3A mutations in lung cancer patients who developed drug resistance after treatment with sequential targeted therapies. These data suggest that induction of A3A mutagenesis in response to targeted therapy treatment may facilitate the development of acquired resistance in non-small-cell lung cancer. Thus, suppressing expression or enzymatic activity of A3A may represent a potential therapeutic strategy to prevent or delay acquired resistance to lung cancer targeted therapy.

[1]  Nuno A. Fonseca,et al.  Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples , 2020, Nature Communications.

[2]  M. Lawrence,et al.  Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition , 2020, npj Precision Oncology.

[3]  L. Zou,et al.  Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots , 2020, Nature Communications.

[4]  Icgc,et al.  Pan-cancer analysis of whole genomes , 2017, bioRxiv.

[5]  A. Bardelli,et al.  Adaptive mutability of colorectal cancers in response to targeted therapies , 2019, Science.

[6]  D. Pe’er,et al.  Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  L. Sequist,et al.  Patient-specific tumor growth trajectories determine persistent and resistant cancer cell populations during treatment with targeted therapies. , 2019, Cancer research.

[8]  Michael S. Lawrence,et al.  Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features , 2019, Science.

[9]  M. Stratton,et al.  Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis , 2019, Cell.

[10]  S. Digumarthy,et al.  Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. , 2018, JCO precision oncology.

[11]  Li Ding,et al.  Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. , 2018, Cell systems.

[12]  M. Lawrence,et al.  SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors , 2018, Nature Medicine.

[13]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[14]  David J. Arenillas,et al.  JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework , 2017, Nucleic acids research.

[15]  M. Lawrence,et al.  Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. , 2018, Cancer discovery.

[16]  Maximilian Diehn,et al.  Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers , 2017, Nature Genetics.

[17]  M. Lawrence,et al.  APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition. , 2017, Cancer research.

[18]  Nicholas A. Sinnott-Armstrong,et al.  An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues , 2017, Nature Methods.

[19]  William J. Greenleaf,et al.  chromVAR: Inferring transcription factor-associated accessibility from single-cell epigenomic data , 2017, Nature Methods.

[20]  Sydney M. Shaffer,et al.  Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance , 2017, Nature.

[21]  P. Park,et al.  Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Nicolai J. Birkbak,et al.  Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[23]  Lauren L. Ritterhouse,et al.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. , 2016, Cancer discovery.

[24]  HaroldC. Smith,et al.  The APOBEC Protein Family: United by Structure, Divergent in Function. , 2016, Trends in biochemical sciences.

[25]  Aaron T. L. Lun,et al.  From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline , 2016, F1000Research.

[26]  Chandra Sekhar Pedamallu,et al.  Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas , 2016, Nature Genetics.

[27]  Fidel Ramírez,et al.  deepTools2: a next generation web server for deep-sequencing data analysis , 2016, Nucleic Acids Res..

[28]  M. Weitzman,et al.  APOBEC3A damages the cellular genome during DNA replication , 2016, Cell cycle.

[29]  Bruce A. Posner,et al.  Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells , 2016, Nature Communications.

[30]  P. Mieczkowski,et al.  APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication. , 2016, Cell reports.

[31]  P. Hanawalt,et al.  Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair , 2016, Cell.

[32]  G. Getz,et al.  Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition , 2016, Nature Medicine.

[33]  G. Getz,et al.  Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. , 2016, The New England journal of medicine.

[34]  Gad Getz,et al.  An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers , 2015, Nature Genetics.

[35]  Sourav Bandyopadhyay,et al.  NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. , 2015, Cell reports.

[36]  G. Getz,et al.  RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer , 2015, Nature Communications.

[37]  Feng Zhang,et al.  Genome engineering using CRISPR-Cas9 system. , 2015, Methods in molecular biology.

[38]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[39]  Z. Szallasi,et al.  Spatial and temporal diversity in genomic instability processes defines lung cancer evolution , 2014, Science.

[40]  N. McGranahan,et al.  Chromosomal instability selects gene copy-number variants encoding core regulators of proliferation in ER+ breast cancer. , 2014, Cancer research.

[41]  David Hsu,et al.  OpenComet: An automated tool for comet assay image analysis , 2014, Redox biology.

[42]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[43]  Howard Y. Chang,et al.  Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position , 2013, Nature Methods.

[44]  Steven A. Roberts,et al.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers , 2013, Nature Genetics.

[45]  S. Wain-Hobson,et al.  Human APOBEC3A Isoforms Translocate to the Nucleus and Induce DNA Double Strand Breaks Leading to Cell Stress and Death , 2013, PloS one.

[46]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[47]  Jiri Bartek,et al.  Replication stress links structural and numerical cancer chromosomal instability , 2013, Nature.

[48]  Jason B. Nikas,et al.  APOBEC3B is an enzymatic source of mutation in breast cancer , 2013, Nature.

[49]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[50]  S. Gabriel,et al.  Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability , 2012, Genome research.

[51]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[52]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[53]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[54]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[55]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[56]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[57]  Sung-Liang Yu,et al.  Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  D. Firsanov,et al.  H2AX phosphorylation at the sites of DNA double-strand breaks in cultivated mammalian cells and tissues , 2011, Clinical Epigenetics.

[59]  M. Weitzman,et al.  APOBEC3A can activate the DNA damage response and cause cell‐cycle arrest , 2011, EMBO reports.

[60]  Ryohei Katayama,et al.  Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK , 2011, Proceedings of the National Academy of Sciences.

[61]  H. Hieronymus,et al.  FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR , 2011, Nature.

[62]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[63]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[64]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[65]  Steven J. M. Jones,et al.  Circos: an information aesthetic for comparative genomics. , 2009, Genome research.

[66]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[67]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[68]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[69]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.